H. g K. g E cha ge, a d Clea i g Limi ed a d The S . ck E cha ge . f H. g K. g Limi ed ake . e, . , ibili f. he c. e , . f hi, a . . ceme , make . e e, e a i. a, . i, acc. ac . c. m le e e, a d e e, l di, claim a liabili ha, . e e f. a l. , h. , . e e a i, i g f . m . i elia ce . . he h. le . a a . f he c. e , . f hi, a . . ceme .

JOINN LABORATORIES (CHINA) CO., LTD.
北京昭衍新藥研究中心股份有限公司

(A j. i , . ck c. m a i c. . a ed i he Pe. le', Re . blic . f Chi a i h limi ed liabili)

(Stock code: 6127)

CONTINUING CONNECTED TRANSACTIONS:

(1) 2026 STAIDSON RESEARCH AND DEVELOPMENT SERVICE FRAMEWORK AGREEMENT; AND
(2) 2026 BIOAI SERVICE FRAMEWORK AGREEMENT

BACKGROUND

[illegible]

[illegible]

IMPLICATIONS UNDER THE LISTING RULES

[illegible] 31.01% [illegible] 1.96% [illegible] 16 (華泰證券資管－招商銀行－華泰聚力16號集合資產管理計劃), [illegible] 6.20% [illegible]; [illegible] 81.57% [illegible] 2026 [illegible] 14A [illegible]

A [illegible] 2026 A [illegible] 0.1% [illegible] 5%, [illegible] 14A [illegible].

BACKGROUND

[illegible] : (i) [illegible] 20 [illegible] 2024 [illegible] 2025 [illegible] A [illegible]; [illegible] (ii) [illegible] 30 A[illegible] 2024 [illegible] 2024 [illegible] A [illegible] 28 [illegible] 2025 [illegible] A [illegible] 31 [illegible] 2025.

[illegible] 5 [illegible] 2025 ([illegible]), [illegible] (i) [illegible] 2026 [illegible] A [illegible] 1 [illegible] 2026 [illegible] 31 [illegible] 2026; [illegible] (ii) [illegible] 2026 [illegible] A [illegible] 1 [illegible] 2026 [illegible] 31 [illegible] 2026.

CONTINUING CONNECTED TRANSACTIONS

2026 Staidson Research and Development Service Framework Agreement

[illegible] 2026 [illegible] A [illegible]:

[illegible]:	5 [illegible] 2025
[illegible]:	(i) [illegible] ([illegible]); [illegible]
	(ii) [illegible] ([illegible])
[illegible]:	[illegible] 1 [illegible] 2026 [illegible] 31 [illegible] 2026
[illegible]:	[illegible] ([illegible] **Staidson Services**•)

[illegible]：[illegible]

[illegible]：[illegible]

Historical Annual Caps and Transaction Amounts in relation to the Staidson Services

[illegible]

[illegible]

	For the year ended 31 December		
	2023	**2024**	**2025**
	(RMB milli[illegible])	*(RMB milli[illegible])*	*(RMB milli[illegible])*
[illegible]	80	75	50

[illegible]

	For the year ended 31 December 2023 *(RMB milli[illegible])*	For the year ended 31 December 2024 *(RMB milli[illegible])*	For 1 January 2025 to 31 October 2025 *(RMB milli[illegible])*
[illegible]	74.19	21.97	12.20

Proposed Annual Cap and Basis for Annual Cap under the 2026 Staidson Research and Development Service Framework Agreement

[illegible] 2026 [illegible]:

	For the year ending 31 December 2026 *(RMB milli[illegible])*
[illegible] 2026 [illegible]	47.00

[illegible] 31 [illegible] 2026 [illegible] 31 [illegible] 2026; [illegible]

[illegible] 47 [illegible] 0.1% [illegible] 5%. [illegible] 2026 [illegible] 14A [illegible]

2026 BioAI Service Framework Agreement

[illegible] 2026 [illegible]:

[illegible]: [illegible] 5 [illegible] 2025 ([illegible])

[illegible]: [illegible] (,) [illegible] ([illegible]); [illegible]

Historical Annual Caps and Transaction Amounts in relation to the BioAI Services

[illegible]

[illegible]

	For the year ended 31 December	
	2024	**2025**
	(RMB milli[illegible])	*(RMB milli[illegible])*
[illegible]	17	21

[illegible]

	For the year ended 31 December 2024	For 1 January 2025 to 31 October 2025
	(RMB milli[illegible])	*(RMB milli[illegible])*
[illegible]	9.03	4.48

Proposed Annual Cap and Basis for Annual Cap under the 2026 BioAI Service Framework Agreement

[illegible] 2026 [illegible]:

	For the year ending 31 December 2026
	(RMB milli[illegible])
[illegible]	16.50

[illegible]

[illegible] 16.5 [illegible] 0.1% [illegible] 5%. [illegible] 2026 [illegible] 14A [illegible]

REASONS FOR AND BENEFITS OF THE 2026 AGREEMENTS

The 2026 Staidson Research and Development Service Framework Agreement

[illegible] 2026 [illegible]

The 2026 BioAI Service Framework Agreement

[illegible]

OPINIONS OF THE BOARD

[illegible] 2026 [illegible] 2026 [illegible]

[illegible] 2026 [illegible] 2026 [illegible]

INTERNAL CONTROL MEASURES

[illegible] 2026 A[illegible]:

[illegible] 2026 A[illegible];

[illegible] 2026 A[illegible];

[illegible] 2026 A[illegible] ([illegible]);

[illegible] 2026 A[illegible] 2026 A[illegible].

[illegible] 14A [illegible].

INFORMATION OF THE PARTIES

Information of the Group

[illegible] & [illegible] & [illegible] &

Information of Staidson

[illegible] 16 A[illegible] 2002 [illegible] (: 300204). [illegible] 31.01% [illegible] ([illegible]) ([illegible] 85% [illegible]), 1.96% [illegible] A [illegible] A [illegible] 16 (華泰證券資管－招商銀行－華泰聚力16號集合資產管理計劃) [illegible] 6.20% [illegible]

[illegible]

Information of BioAI

[illegible] 81.57% [illegible] ([illegible]). [illegible] 18.43% [illegible] ( ) [illegible] 9.54% [illegible] ; (_) [illegible] 0.2% [illegible] (馮宇靜), [illegible] ; (_) [illegible] 8.69% [illegible] 5% [illegible] .

[illegible]

IMPLICATIONS UNDER THE LISTING RULES

A [illegible], (_) [illegible] 31.01% [illegible] ( ), 1.96% [illegible] A [illegible] 16 (華泰證券資管－招商銀行－華泰聚力16號集合資產管理計劃), [illegible] 6.20% [illegible] ; (_) A [illegible] 81.57% [illegible] . A [illegible] A [illegible] ([illegible]), [illegible] 2026 A [illegible] 14A [illegible] .

A [illegible] 2026 A [illegible] 0.1% [illegible] 5%, [illegible] 14A [illegible] .

[illegible] 2026 A[illegible] (,) [illegible] (,) [illegible] 81.57% [illegible] 2026 A[illegible]

DEFINITIONS

[illegible]:

2024 [illegible]	[illegible] 30 A[illegible] 2024 [illegible] 1 [illegible] 2024 [illegible] 31 [illegible] 2025
2025 [illegible]	[illegible] 20 [illegible] 2024 [illegible] 1 [illegible] 2025 [illegible] 31 [illegible] 2025
2026 A[illegible]	2026 [illegible] 2026 [illegible]
2026 [illegible]	[illegible] 5 [illegible] 2025 [illegible] 1 [illegible] 2026 [illegible] 31 [illegible] 2026
2026 [illegible]	[illegible] 5 [illegible] 2025 [illegible] 1 [illegible] 2026 [illegible] 31 [illegible] 2026
[illegible] ( )[illegible]	[illegible]
A[illegible]	A[illegible] (生全智能科技(北京)有限公司)
[illegible]	[illegible]
[illegible]	[illegible] (北京昭衍新藥研究中心股份有限公司), [illegible]

(高大鵬),

(周志文),

(馮宇霞),

(舒泰神(北京)生物製藥股份有限公司),

: 300204)

(熠昭(北京)醫藥科技有限公司), 85%

%

JOINN Laboratories (China) Co., Ltd.
Feng Yuxia
Chai e

5 2025

A a he da e f hi a ceme , he B a d c mu i e M . Fe g Y. ia a he Chai e a d e ec. i e Di ec , M . S. Y. ia, M . Ga Da e g, M . G. Ji glia g a d M . L. Xi a e ec. i e Di ec , M . Zha g Fa , M . Ya g Cha g , M . Ya g F. a a d M . Yi g Fa g ia a i de e de -e ec. i e Di ec , a d M . Li Ye a emu l. ee Di ec .